CD274 and non-small cell lung carcinoma: Studies demonstrate that combining programmed death-1/programmed death ligand 1 (PD-1/PD-L1) checkpoint blockade immunotherapies with the anti-angiogenic agent bevacizumab significantly enhances overall survival in non-small cell lung cancer (NSCLC) patients (13).